FXR
Farnesoid X Receptor (FXR) is a nuclear receptor that plays a key role in the regulation of bile acid homeostasis, lipid metabolism, and glucose regulation. FXR is a potential therapeutic target for treating liver diseases, metabolic disorders, and cardiovascular diseases. FXR inhibitors can modulate these pathways, offering insights into disease mechanisms and therapeutic strategies. At CymitQuimica, we provide a range of FXR inhibitors to support your research in hepatology, metabolism, and drug development.
Found 67 products for "FXR".
Filter by
Purity percentage
0
100
|
0
|
50
|
90
|
95
|
100
- Lower prices
- Higher prices
- Lower purities
- Higher purities
- Faster estimated delivery
Ursodeoxycholic acid
CAS:Ursodeoxycholic acid (UDCA) is a potent inhibitor of liver-specific fatty acid transporter 5 (FATP5),inhibits cholesterol absorption. High-Quality, Low-Cost!Formula:C24H40O4Purity:99.48% - ≥95%Color and Shape:White SolidMolecular weight:392.572LY2562175
CAS:LY2562175 is an effective and selective FXR agonist (EC50: 193 nM).Formula:C28H27Cl2N3O4Purity:99.16% - 99.63%Color and Shape:SolidMolecular weight:540.438Chenodeoxycholic acid
CAS:Chenodeoxycholic acid (CDCA) is a bile acid that inhibits 11β-HSD2 with an IC50 value of 22 mM. High-Quality, Low-Cost!Formula:C24H40O4Purity:99.70% - 99.93%Color and Shape:White SolidMolecular weight:392.572Tauro-β-muricholic acid sodium
CAS:Tauro-β-muricholic Acid sodium is a endogenous metabolite, is a competitive and reversible antagonist of farnesoid X receptor (FXR)(IC50 of 40 μM).Formula:C26H44NNaO7SPurity:98%Color and Shape:SolidMolecular weight:537.69FXR/TGR5 agonist 1
CAS:FXR/TGR5 agonist 1 acts as an agonist on both FXR and TGR5 receptors and is utilized for treating fatty liver disease.Formula:C31H32ClN3O3Color and Shape:SolidMolecular weight:530.07Fexarene
CAS:Fexarene is a non-steroidal FXR agonist.Formula:C32H33NO3Purity:98%Color and Shape:SolidMolecular weight:479.62LH10
LH10 is an FXR agonist based on fexaramine, with an EC50 of 0.14 μM. It offers hepatoprotective effects, mitigating conditions such as cholestasis induced by alpha naphthylisothiocyanate (ANIT), acute liver injury caused by APAP, and non-alcoholic steatohepatitis (NASH).Formula:C34H33N3O2Color and Shape:SolidMolecular weight:515.64F44-A13
CAS:F44-A13 is an orally active, highly selective farnesoid X receptor (FXR) antagonist with an IC50 value of 1.1 μM. It optimizes cholesterol metabolism and reduces activity by inducing CYP7A1 expression, lowering cholesterol, triglycerides, and low-density lipoprotein cholesterol (LDL-C) levels in mouse models. F44-A13 is applicable for studying metabolic diseases associated with lipid disorders [1].Formula:C28H40N4O5SColor and Shape:SolidMolecular weight:544.71FXR agonist 5
CAS:FXR agonist 5 is an FXR agonist used in the study of liver diseases or diseases mediated by metabolic inflammation.Formula:C40H53N5O5Purity:99.74%Color and Shape:White SolidMolecular weight:683.88FXR agonist 10
FXR agonist10 (Compound 27) acts as an agonist for FXR with an EC50 of 14.26 μM. It increases the expression of SHP and BSEP proteins while decreasing the expression of NTCP and CYP7A1 proteins. Additionally, FXR agonist10 has been shown to ameliorate ANIT-induced cholestasis in mouse models.Formula:C15H22O4Color and Shape:SolidMolecular weight:266.33Nuclear Receptor Compound Library
A unique collection of xnum nuclear receptor signaling targeted compounds for high throughput and high content screening;Color and Shape:Odour SolidZLY28
ZLY28 is a novel, first-in-class compound with specific intestinal restriction and oral activity, serving as a dual modulator of FXR and FABP1.Formula:C29H23Cl2NO4Purity:98%Color and Shape:SolidMolecular weight:520.4dual FXR/PPARδ agonist-2
Dual FXR/PPARδ agonist-2 is a dual agonist for FXR and PPARδ, derived from the hybridization of the FXR agonist GW-4064 and the PPARδ agonist GW-0742. It exhibits potent dual-target activity, with an EC50 of 12.28 nM for FXR activation and a 69% activation rate of PPARδ at a concentration of 100 nM. Additionally, dual FXR/PPARδ agonist-2 demonstrates antifibrotic effects in a mouse model of pulmonary fibrosis.LZ-007
CAS:LZ-007 is an agonist of the Farnesoid X receptor (FXR), with an EC50 of 51 nM as determined by TR-FRET assay, and an EC50 of 76 nM in HepG2 cells. It exhibits favorable pharmacokinetic properties in SD rats and can improve metabolic dysfunction-associated steatohepatitis induced by high-fat diets and CCl4 in mice.Formula:C27H29F3N2O5Color and Shape:SolidMolecular weight:518.53Tauro-obeticholic acid-d4
Tauro-obeticholic acid-d4 is the deuterium-labeled form of Tauro-obeticholic acid. Tauro-obeticholic acid functions as the active metabolite of taurine. Obeticholic acid is an orally bioavailable farnesoid X receptor (FXR) agonist.Linafexor
CAS:Linafexor, Non-steroidal FXR agonist, for primary sclerosing cholangitis (PSC) and non-alcoholic steatohepatitis (NASH).Formula:C28H25Cl2FN4O4Purity:99.76%Molecular weight:571.43NR1H4 Protein, Human, Recombinant (His)
NR1H4 Protein, Human, Recombinant (His) is expressed in E.Color and Shape:Lyophilized PowderMolecular weight:27.83 kDa (predicted)NR1H4 Protein, Mouse, Recombinant (His)
NR1H4 Protein, Mouse, Recombinant (His) is expressed in E. coli expression system with His tag. The predicted molecular weight is 27.80 kDa.Color and Shape:Lyophilized PowderMolecular weight:27.80 kDa (predicted)16-Dehydropregnenolone Acetate
CAS:16-Dehydropregnenolone acetate: an oral sterol inhibiting 17α-hydroxylase and 5α-reductase. Lowers lipids, fights cancer, and synthesizes dexamethasone.Formula:C23H32O3Purity:97.02%Color and Shape:SolidMolecular weight:356.50FXR agonist 3
FXR agonist 3 is an anti NASH compound with anti-fibrotic and active properties that inhibits the expression of COL1A1, TGF-β1, α-SMA and TIMP1.Formula:C28H28BrNO4Purity:95.04%Color and Shape:Yellow SolidMolecular weight:521.12
